Sign inCreate account

Report workspace tools

NCT04992247WITHDRAWNanonymous

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

PHASE2

Modality

AI-normalized

protein therapy

Target

AI-normalized

COVI-MSC, Placebo

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVI-MSC, Placebo

Source & freshness

Source record

NCT ID

NCT04992247

Original source

ClinicalTrials.gov

Source last updated

Apr 17, 2024

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04992247

Title

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Sponsor

Sorrento Therapeutics, Inc.

Status

WITHDRAWN

Phase

PHASE2

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

COVI-MSC, Placebo

Target normalized

COVI-MSC, Placebo

Interventions

COVI-MSC, Placebo

Public preview

Source record

This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04992247

Status

WITHDRAWN

Phase

PHASE2

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 17, 2024
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04992247

Indication

Covid19

Modality

protein therapy

Target

COVI-MSC, Placebo

Intervention

COVI-MSC, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.